Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
American Heart Association
Biotech
AZ's oral PCSK9 inhibitor halves bad cholesterol in phase 2
AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks at its highest dose, hitting the goal of a phase 2 trial.
James Waldron
Mar 31, 2025 12:00pm
Boston Scientific, Abbott tout long-term heart occluder data
Nov 19, 2024 12:00pm
Ablation before meds shows gains in v-tach after heart attack
Nov 18, 2024 11:45am
AI spots high blood pressure, diabetes in slow-motion video
Nov 18, 2024 11:30am
Wireless pacemakers for kids show promise, but challenges remain
Apr 12, 2023 10:00am
AHA: Wearables severely underused by those with heart disease
Oct 31, 2022 11:58am
